Research: DiNICOLANTONIO and COLLEAGUES,

Listed in Issue 221

Abstract

DiNICOLANTONIO and COLLEAGUES,  Mid America Heart Institute, Saint Luke's Hospital, Kansas City, USA. jjdinicol@gmail.com , Heart Hospital, University College London Hospitals UCLH, London-UK. Mid America Heart institute at Saint Luke's Hospital and University of Missouri-Kansas City, Kansas City, USA evaluate and explore whether there may be further explanations in recent omega-3 trials to explain why recent trials testing omega-3s have not confirmed their benefits in coronary heart disease CHD.

Background

Multiple trials over the past two decades testing omega-3 polyunsaturated fatty acids (PUFAs), containing eicosapentaenoic acid (EPA) and or docosahexaenoic acid (DHA), have shown substantial benefits for reducing major coronary heart disease (CHD) events, all-cause mortality, cardiovascular (CV) death, sudden cardiac death (SCD), and stroke.

Methodology

However, recent trials testing omega-3s have generally failed to confirm these benefits.

Results

While increased fish and fish oil intake among the general population, increased use of optimal medical therapy (including statins, aspirin, and modern antihypertensive medications) probably make it more challenging for fish oil supplementation to show additional benefits, there might be further explanations in the formulation, dosage, and comparator used in these recent omega-3 trials.

Conclusion

References

DiNicolantonio JJ, Meier P and O'Keefe JH. Omega-3 polyunsaturated fatty acids for the prevention of cardiovascular disease: do formulation, dosage & comparator matter? Mo Med. Nov-Dec 2013.110(6): 495-8.

Munro Hall Clinic 2019

IJCA 2018 New Skyscraper

Scientific and Medical Network 2

Cycle India 2020

Walk on the Wide Side Trek Kenya 2020

Big Heart Bike Ride South Africa 2020

top of the page